Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
203.90
+0.83 (0.41%)
At close: Nov 21, 2025, 4:00 PM EST
204.40
+0.50 (0.25%)
After-hours: Nov 21, 2025, 7:58 PM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.33
Revenue / Employee
$667,263
Employees
138,100
Market Cap
491.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
JNJ News
- 3 days ago - Why biotech and drug stocks are on the mend even though the rest of the market is hurting - Market Watch
- 3 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 4 days ago - Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy - Business Wire
- 4 days ago - Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion - WSJ
- 4 days ago - Halda Therapeutics Announces Acquisition by Johnson & Johnson - GlobeNewsWire
- 4 days ago - J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion - Reuters
- 4 days ago - New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis - PRNewsWire